SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin

NCT07560566 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Hepato Cellular Carcinoma (HCC)
Hand Foot Skin Syndrome

Interventions

DRUG: Topical Indomethacin

Sponsor

National Taiwan University Hospital